Jay Olson

Oppenheimer | Healthcare

Jay Olson is an analyst from Oppenheimer specializing in the Healthcare sector. Ranked #3 out of 4553 analysts, they have issued 22 stock ratings with a success rate of 84.26% and an average return of 527.81%.

Jay Olson has a well-established track record, with 22 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 84.26% and an average return of 527.81%, underscoring their expertise and ability to identify winning opportunities for investors.

#3

Out of 4553

22

Total Ratings

+84.26%

Success Rate

+527.81%

Average Return

Recent Ratings Analysis

BIOA

Feb 25, 2026

Target

$60.00

Current

$22.14

Performance

0.00%

Jay Olson rated BIOA as Outperform on Feb 25, 2026, setting a price target of 60. Shares have remained stable near 22.14, leaving the 60 target still in play.

VRTX

Feb 13, 2026

Target

$540.00

Current

$483.05

Performance

-1.71%

On Feb 13, 2026, VRTX was given a Outperform rating by Jay Olson, with a target price of 540. The stock traded sideways with a -1.71% move, keeping the bullish thesis unresolved.

ACAD

Feb 06, 2026

Target

$23.00

Current

$24.97

Performance

5.98%

ACAD received a Perform rating from Jay Olson on Feb 06, 2026, aiming for 23. Investors saw gains of 5.98% that the cautious stance didn’t fully capture.

BIIB

Jan 30, 2026

Target

$225.00

Current

$190.73

Performance

6.03%

On Jan 30, 2026, Jay Olson published a Outperform outlook on BIIB, with a target of 225. Shares gained 6.03%, underscoring the accuracy of the bullish outlook toward 225.

RVMD

Jan 27, 2026

Target

$150.00

Current

$103.24

Performance

3.43%

Jay Olson on Jan 27, 2026 assigned RVMD a Outperform rating, with a price target of 150. The recommendation remains pending validation as shares consolidate around 103.24.

CHRS

Jan 22, 2026

Target

$10.00

Current

$1.68

Performance

5.66%

On Jan 22, 2026, Jay Olson reaffirmed CHRS with a Outperform rating, targeting 10. The recommendation was supported by strong follow-through as the stock rose from 1.68 to 1.68.

PRAX

Dec 15, 2025

Target

$750.00

Current

$347.55

Performance

25.74%

PRAX was rated Outperform by Jay Olson on Dec 15, 2025, with a price objective of 750. A bullish response from the market helped close the gap of 402.45 to the target.

TERN

Dec 09, 2025

Target

$58.00

Current

$41.38

Performance

-2.80%

On Dec 09, 2025, Jay Olson initiated coverage on TERN with a Outperform rating and target of 58. Neutral price movement of -2.80% leaves room for interpretation.

MDGL

Nov 20, 2025

Target

$650.00

Current

$435.01

Performance

-19.76%

Jay Olson issued a Outperform recommendation for MDGL on Nov 20, 2025, price target set at 650. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

IBIO

Oct 21, 2025

Target

$5.00

Current

$2.87

Performance

158.56%

On Oct 21, 2025, IBIO was evaluated by Jay Olson, who gave a Outperform rating and target of 5. This case illustrates how a timely bullish rating can translate into tangible gains of 158.56%.

IONS

Oct 08, 2025

Target

$90.00

Current

$80.93

Performance

15.68%

Jay Olson rated IONS as Outperform on Oct 08, 2025, setting a price target of 90. The call has proven timely, with shares rising 15.68% toward the price target of 90.

IMRX

Sep 25, 2025

Target

$30.00

Current

$5.24

Performance

-34.50%

On Sep 25, 2025, IMRX was given a Outperform rating by Jay Olson, with a target price of 30. Despite the Buy call, shares fell from 5.24 to 5.24, challenging the optimistic stance.

BCYC

Aug 11, 2025

Target

$44.00

Current

$5.73

Performance

-23.19%

BCYC received a Outperform rating from Jay Olson on Aug 11, 2025, aiming for 44. The rating hasn’t played out as hoped, with the stock trading 23.19% below expectations.

MNMD

Aug 04, 2025

Target

$25.00

Current

$17.51

Performance

87.07%

On Aug 04, 2025, Jay Olson published a Outperform outlook on MNMD, with a target of 25. Shares gained 87.07%, underscoring the accuracy of the bullish outlook toward 25.

ATAI

Jul 29, 2025

Target

$14.00

Current

$4.34

Performance

31.12%

Jay Olson on Jul 29, 2025 assigned ATAI a Outperform rating, with a price target of 14. The Buy call aligned well with market performance, producing a gain of 31.12%.

PRTA

May 27, 2025

Target

$0.00

Current

$8.88

Performance

93.89%

On May 27, 2025, Jay Olson reaffirmed PRTA with a Perform rating, targeting null. Market strength beyond 8.88 went further than the conservative outlook suggested.

JSPR

May 15, 2025

Target

$65.00

Current

$1.40

Performance

-71.25%

JSPR was rated Outperform by Jay Olson on May 15, 2025, with a price objective of 65. This case shows how bullish projections can fail, with the stock now below 1.4.

NKTR

Mar 14, 2025

Target

$6.00

Current

$70.37

Performance

7746.79%

On Mar 14, 2025, Jay Olson initiated coverage on NKTR with a Outperform rating and target of 6. The stock’s climb of 7746.79% since the call highlights the foresight in the rating.

DNLI

Mar 03, 2025

Target

$42.00

Current

$22.29

Performance

46.64%

Jay Olson issued a Outperform recommendation for DNLI on Mar 03, 2025, price target set at 42. Investors following the Buy call captured upside momentum, with shares now at 22.29.

EXEL

Jan 24, 2025

Target

$33.00

Current

$44.75

Performance

38.20%

On Jan 24, 2025, EXEL was evaluated by Jay Olson, who gave a Perform rating and target of 33. Investors who stayed in despite the Hold saw upside of 38.20%.

NTLA

Jan 13, 2025

Target

$40.00

Current

$13.42

Performance

33.53%

Jay Olson rated NTLA as Outperform on Jan 13, 2025, setting a price target of 40. The call has proven timely, with shares rising 33.53% toward the price target of 40.

QTTB

Dec 11, 2024

Target

$20.00

Current

$4.73

Performance

-20.50%

On Dec 11, 2024, QTTB was given a Outperform rating by Jay Olson, with a target price of 20. Despite the Buy call, shares fell from 4.73 to 4.73, challenging the optimistic stance.

SGMT

Dec 06, 2024

Target

$30.00

Current

$6.13

Performance

20.20%

SGMT received a Outperform rating from Jay Olson on Dec 06, 2024, aiming for 30. Momentum has favored the Buy call, with shares climbing from 6.13 to 6.13, rewarding those who trusted the recommendation.

INO

Nov 18, 2024

Target

$15.00

Current

$1.85

Performance

-54.66%

On Nov 18, 2024, Jay Olson published a Outperform outlook on INO, with a target of 15. Market action contradicted the Buy thesis, as shares slipped to 1.85.

GLTO

Oct 17, 2024

Target

$10.00

Current

$32.30

Performance

379.94%

Jay Olson on Oct 17, 2024 assigned GLTO a Outperform rating, with a price target of 10. The Buy call aligned well with market performance, producing a gain of 379.94%.

VKTX

Sep 25, 2024

Target

$138.00

Current

$33.12

Performance

-47.54%

On Sep 25, 2024, Jay Olson reaffirmed VKTX with a Outperform rating, targeting 138. Shares slid 47.54% despite the recommendation, highlighting downside risks.

MRNS

Sep 23, 2024

Target

$6.00

Current

$0.55

Performance

-66.26%

MRNS was rated Outperform by Jay Olson on Sep 23, 2024, with a price objective of 6. This case shows how bullish projections can fail, with the stock now below 0.55.

GANX

Aug 14, 2024

Target

$8.00

Current

$2.52

Performance

125.00%

On Aug 14, 2024, Jay Olson initiated coverage on GANX with a Outperform rating and target of 8. The stock’s climb of 125.00% since the call highlights the foresight in the rating.

NBIX

Aug 02, 2024

Target

$219.00

Current

$131.15

Performance

-14.36%

Jay Olson issued a Outperform recommendation for NBIX on Aug 02, 2024, price target set at 219. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

INCY

Jul 26, 2024

Target

$81.00

Current

$99.98

Performance

45.72%

On Jul 26, 2024, INCY was evaluated by Jay Olson, who gave a Outperform rating and target of 81. This case illustrates how a timely bullish rating can translate into tangible gains of 45.72%.

EDIT

Jun 18, 2024

Target

$12.00

Current

$2.13

Performance

-57.74%

Jay Olson rated EDIT as Perform on Jun 18, 2024, setting a price target of 12. The cautious Hold call aligned with subsequent weakness, as shares slipped 57.74%.

CRSP

May 10, 2024

Target

$95.00

Current

$55.20

Performance

7.88%

On May 10, 2024, CRSP was given a Outperform rating by Jay Olson, with a target price of 95. The stock rallied 7.88% after the rating, narrowing the gap to the target of 95 and validating the bullish stance.

Frequency Asked Questions

Who is Jay Olson?

Jay Olson is an analyst from Oppenheimer specializing in the Healthcare sector.

What is Jay Olson's success rate?

Jay Olson currently has a success rate of +84.26%.

How many ratings has Jay Olson issued?

Jay Olson has issued 22 stock ratings so far.

What is the average return of Jay Olson's calls?

Their stock ratings have generated an average return of +527.81%.

What is Jay Olson's ranking?

Jay Olson is ranked #3 out of 4553 analysts.

What types of ratings does Jay Olson give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Jay Olson?

You can follow Jay Olson by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Jay Olson?

Their latest rating was a Buy on BIOA issued on 2026-02-25.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep